ReviewVirology journal2025
Aptamer as a therapeutic agent for dengue infections.
Review in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dengue virus (DENV) poses a significant global health burden, with current treatments being limited and primarily supportive. Aptamers are an emerging class of molecular recognition elements that are cheaper, less immunogenic and have no batch-to-batch variation as compared to antibodies. In light of their advantages, aptamers can potentially offer a novel approach to counteract DENV by targeting viral proteins or host factors essential for viral replication and pathogenesis. This review gleans the recent advancements in the development of aptamer-based therapeutic agents targeting dengue virus infection. The latest advancement on aptamers targeting specific dengue virus components such as capsid protein (C), envelope domain III (E3), and nonstructural proteins (NS); and their roles in inhibiting viral replication are highlighted. Although the development of aptamers as potential therapeutics for dengue infections is still in its early stages, based on their therapeutic potentiality, they hold immense potential for dengue viral treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.